Since launch we've been asked a version of the same question: is MINX, our extended-release oral minoxidil compounded under section 503A, safer than the standard 5 mg oral minoxidil that most dermatologists prescribe off-label for hair loss?

The short answer: we do not know yet, and saying anything stronger than that would be dishonest. What follows is what we do know, what the pharmacology suggests, what early patient feedback hints at, and what we are doing to actually find out.

What we have so far

Two patients who could not tolerate standard oral minoxidil at the same or a lower dose have reported improvement in side effects after switching to MINX. These are individual patient reports, not a controlled study. They are not proof that MINX is safer. They are the kind of signal that motivates a real investigation, not the kind that ends one.

Why pharmacology predicts a difference for acute effects

Standard oral minoxidil at 5 mg produces a sharp plasma peak of approximately 37 ng/mL within roughly 30 minutes, then declines¹. This peak exceeds the level at which heart-rate effects first become detectable. The topical minoxidil product monograph reports that a 6.86 mg oral dose, yielding a serum concentration around 21.7 ng/mL, was the lowest dose distinguishable from placebo on heart rate⁸. A standard 5 mg oral dose crosses that line within the first hour.

The acute cardiovascular liabilities of minoxidil, racing heart, palpitations, lightheadedness, are widely understood to be driven by how high and how fast the plasma concentration rises, not by the total amount of drug in the system. Reduction of peripheral arteriolar resistance triggers a baroreflex response, which is what the patient feels⁷. Flattening the curve at the same daily dose should, in theory, reduce that signal.

In our published pharmacokinetic data, the MINX fed C_max was approximately 6.5 ng/mL at 9 to 10 hours, roughly six-fold below the immediate-release peak and three- to four-fold below the 21.7 ng/mL anchor. Total exposure (AUC) is comparable. That is the case for expecting fewer acute side effects, and it is the most defensible mechanistic prediction we can make.

Why the long-term picture is harder

Acute effects are one bucket. Long-term effects are a different bucket and the pharmacology is less neat. Fluid retention, weight gain, peripheral edema, the rare pericardial effects: these may track total drug exposure over time, not the peak. If that is right, a smoother curve at the same total dose should not make a difference for those, because MINX delivers the same total minoxidil over the course of a day.

But the early patient reports we have received raise a possibility we did not plan for. If two patients who could not tolerate standard oral minoxidil now tolerate MINX, and the specific side effects they describe (palpitations, periorbital edema) span both the peak-driven and the exposure-driven categories, then maybe the line between those two categories is not as clean as the simple model suggests. Maybe some long-term effects are partly seeded by the size of each daily peak. Or maybe both patients would have improved over time on standard oral minoxidil too, and we are reading a tea leaf.

We do not know which it is. Two patients cannot answer that question.

What the existing safety data says about standard 5 mg oral minoxidil

Before drawing any conclusions about MINX, it is worth recognizing that standard 5 mg oral minoxidil already has a strong safety record at hair-loss doses. The best dedicated cardiac study put 34 men on 5 mg with 24-hour Holter and ambulatory blood pressure monitoring for 24 weeks, and found no symptomatic cardiovascular events, no overall change in mean heart rate, and no significant change in extrasystoles². A 1,404-patient multicenter real-world cohort found systemic adverse effects in 5.5% of patients, with no life-threatening events³. The most common AE was hypertrichosis (15.1%), which is cosmetic, not cardiovascular.

The serious cardiovascular effects most people worry about, pericardial effusion in particular, were historically documented at the 10 to 40 mg range used for severe hypertension, often in patients with pre-existing heart or kidney disease⁴. There is recent FAERS pharmacovigilance signal data suggesting pericardial effusion can be reported at low-dose oral minoxidil too⁵, although FAERS is a passive reporting database and reporting odds ratios are not causal estimates. The honest framing is that pericardial effusion at LDOM doses is rare, often dose-error linked⁶, but not zero-risk.

What we are doing to actually answer the question

Two patient anecdotes cannot settle whether MINX changes the long-term side-effect profile. Neither can a six-month study. What is needed is structured data from real patients on the drug, ideally compared against standard oral minoxidil controls, and ideally tracked for long enough that exposure-driven effects would surface.

We already have enough MINX patients to begin a structured observational survey, and we are emailing the cohort this week to collect baseline tolerability and side-effect data. This is an observational survey, not a registered clinical trial. A formal trial requires IRB review, informed consent, registration, and a protocol, which we will plan separately if the survey signal warrants.

The honest summary

There is a mechanistic reason to expect MINX to reduce acute side effects compared with standard oral minoxidil at the same daily dose. The PK supports it. Two patient reports are consistent with it. That does not equal proof. Whether MINX changes the long-term side-effect profile is genuinely unknown.

The job now is to find out whether a smoother delivery curve buys patients anything beyond the acute peak window, and to do that with real data. If it turns out to be safer, we will earn that finding. We will not market our way to it.

Standard 5 mg oral minoxidil is already a remarkably safe drug at hair-loss doses, supported by 35+ years of post-1979 minoxidil safety data and modern hair-loss cohort studies. MINX is built on top of that safety record.

Sources

1. Fleishaker JC, Andreadis NA, Welshman IR, Wright CE 3rd. The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers. J Clin Pharmacol. 1989;29(2):162-7. PMID: 2715373.
2. Sanabria LM, et al. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022.
3. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-51.
4. Martin WB, Spodick DH, Zins GR. Pericardial Disorders Occurring During Open-Label Study of 1,869 Severely Hypertensive Patients Treated with Minoxidil. J Cardiovasc Pharmacol. 1980;2 (Suppl. 2):S217-S227.
5. Gupta AK, et al. Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions [low-dose oral minoxidil]. J Cosmet Dermatol. 2025.
6. Jiménez-Cauhe J, et al. Low-dose oral minoxidil: adverse events narrative review. J Clin Med. 2025.
7. Loniten (minoxidil) prescribing information. Pfizer, label revised 2015.
8. Topical minoxidil product monograph (referenced as [17] in the MINX paper) for the 21.7 ng/mL heart-rate-effect anchor.